Mesa Biotech Hires Steven Sepulveda to Head Global Business Development and Channel Management
SAN DIEGO, CA – May 10, 2017 – Mesa Biotech Inc., a privately held, molecular diagnostic company that has developed a molecular testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced the appointment of Steven Sepulveda as Vice President Global Business Development and Channel Management. Sepulveda will be responsible for directing and overseeing all aspects of commercial global sales, business development, strategic alliances and distributor relationship management.
“Steven is a critical strategic hire for Mesa Biotech as we prepare for securing our CE-IVD Mark in Europe, FDA approval in the U.S., and product launch in the EU and US,” said Hong Cai, co-founder and CEO of Mesa Biotech. “He has a proven track record leading global medical diagnostic companies, including Quidel, Beckman Coulter, and Sekisui Diagnostics, where he most recently served as Head of Sales and Corporate Alliances. We look forward to his leadership in developing identified markets, achieving our sales plans, and advancing our distribution partnerships.”
Sepulveda comes to Mesa Biotech with more than 26 years of experience in business development, in vitro diagnostic sales and distribution channel management. He got his start in the industry with Quidel Corporation in sales and later advanced into business development and corporate accounts. Sepulveda has held leadership positions with increasing responsibilities leading sales organizations domestically and internationally, overseeing joint ventures, and developing distribution management in health systems. He has served as board member at the Health Industry Distribution Association’s Education Foundation and a number of industry advisory councils. Sepulveda is a graduate of the University of Puerto Rico Medical Science Campus.
About Mesa Biotech Inc.
Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech’s Accula™ System consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to access actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa Biotech’s technology development has been funded to date by a series of grants and private equity investments.
For more information visit http://www.mesabiotech.com.